Read more about the article Ovarian Cancer – Apatinib plus Doxil Yields Significant Efficacy
סרטן השחלות - אפטיניב בתוספת דוקסיל מניב יעילות משמעותית

Ovarian Cancer – Apatinib plus Doxil Yields Significant Efficacy

Background Among women, ovarian cancer is the 5th most common type of cancer. The risk of getting this cancer in one lifetime is 1 in 78. Treatment with Apatinib plus…

Continue ReadingOvarian Cancer – Apatinib plus Doxil Yields Significant Efficacy
Read more about the article Breast Cancer – Benefits of Trodelvy in HR+/HER2-
סרטן שד - יתרונות עם טרודלבי ב HR+/HER2-

Breast Cancer – Benefits of Trodelvy in HR+/HER2-

Background The antibody-drug conjugate Trodelvy offers statistically and clinically significant benefits for patients with heavily pretreated HR+/HER2- breast cancer, according to results of the TROPiCS-02 study, recently presented. HR+/HER2- is…

Continue ReadingBreast Cancer – Benefits of Trodelvy in HR+/HER2-
Read more about the article Cholangiocarcinoma – Imfinzi plus Gemzar and Cisplatin
כולנגיוקרצינומה – אימפינזי פלוס ג'מזר וציספלטין

Cholangiocarcinoma – Imfinzi plus Gemzar and Cisplatin

Background Biliary tract cancer is a group of malignancies that includes intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer. It is typically diagnosed at advanced stages for…

Continue ReadingCholangiocarcinoma – Imfinzi plus Gemzar and Cisplatin
Read more about the article Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+
סרטן רחם - ארימידקס פלוס ויסטוסרטיב במטופלות עם HR+

Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+

Importance Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors, (AIs). The uncontrolled PI3K-AKT-mTOR pathway observed in this type of cancer drives hormonal resistance. Therefore, there is rationale of…

Continue ReadingEndometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+
Read more about the article Lung Cancer – Another new drug for EGFR: Ameile
סרטן ריאה - עוד תרופה חדשה ל-EGFR: Ameile

Lung Cancer – Another new drug for EGFR: Ameile

Background Epidermal Growth Factor Receptor, EGFR, mutations are one of the most common driver mutations in Non–Small-Cell Lung Cancer, NSCLC. Tagrisso, a third-generation EGFR tyrosine kinase inhibitor, TKI, is approved…

Continue ReadingLung Cancer – Another new drug for EGFR: Ameile
Read more about the article Esophageal Cancer – Tislelizumab Beats Chemotherapy
סרטן הוושט – טיסלליזומאב, Tislelizumab, ניצחה כימותרפיה

Esophageal Cancer – Tislelizumab Beats Chemotherapy

Background Patients with advanced or metastatic esophageal cancer of squamous cell type have poor prognosis. For these patients, treatment options are limited after first therapy. Tislelizumab is a humanized monoclonal…

Continue ReadingEsophageal Cancer – Tislelizumab Beats Chemotherapy